
0:00
22:34
The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD.
Related Content:
Więcej odcinków z kanału "JAMA Author Interviews"
Nie przegap odcinka z kanału “JAMA Author Interviews”! Subskrybuj bezpłatnie w aplikacji GetPodcast.